CHMP Recommends GSK's RSV Vaccine Arexvy for Adults 50-59

The European Medicines Agency’s human medicines committee has recommended the use of GSK’s respiratory syncytial virus (RSV) vaccine for adults between the ages of 50 to 59 who are at increased risk of lower respiratory tract disease (LRTD) caused by RSV. This recommendation from the Committee for Medicinal Products for Human Use (CHMP) comes just over a year after the European Commission approved the vaccine, named Arexvy, for adults aged 60 and older.

Should the regulator grant expanded marketing authorisation, Arexvy will become the first RSV vaccine available in Europe specifically for higher-risk adults aged 50 to 59. RSV is a common respiratory virus that typically causes mild, cold-like symptoms. While most individuals recover within a week or two, certain adults, particularly those with comorbidities, weakened immune systems or who are of advanced age, are at a higher risk for severe illness. RSV can exacerbate conditions such as chronic obstructive pulmonary disease (COPD), asthma, and chronic heart failure, potentially leading to severe complications like pneumonia, hospitalisation, or even death.

Arexvy works by including a protein from the surface of the RSV virus, which educates the immune system on how to protect itself against the disease. The CHMP's recommendation was backed by positive outcomes from a late-stage clinical trial that assessed the immune response and safety of Arexvy in adults aged 50 to 59. This trial included participants at increased risk for RSV-LRTD due to pre-existing medical conditions.

This decision also follows the recent approval of Arexvy by the US Food and Drug Administration (FDA) for use in adults aged 50 to 59 who are at an elevated risk of RSV-related LRTD. Tony Wood, GSK’s chief scientific officer, emphasized the significance of expanding RSV immunization benefits to this vulnerable patient group. He noted that for those with underlying medical conditions, RSV could have severe consequences, and expressed pride in being the first to offer protection to these individuals.

GSK is also pursuing regulatory approval to extend the vaccine's use to higher-risk adults aged 50 to 59 in other global markets. Additionally, the company is evaluating the vaccine in younger populations, especially adults aged 18 to 49 with certain underlying medical conditions. 

The expansion of Arexvy's use represents a critical advancement in the fight against RSV, particularly for adults who are more susceptible to severe disease outcomes. The broader availability of this vaccine could significantly reduce the healthcare burden associated with RSV, offering better protection to vulnerable groups and potentially saving lives. As RSV continues to pose a significant health risk, especially among those with other health conditions, the move to include more age groups under the vaccine's protection is a crucial step forward in public health.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!